AVTR | Ticker Profile - Titan Protect

AVTR

Avantor, Inc.

Healthcare · Medical Instruments & Supplies · NYQ

$9.16

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$5.7B

Total market value of the company

Trailing P/E

N/A

Forward P/E

9.86

Based on estimated future earnings — lower means cheaper

Rev Growth

0.0%

Year-over-year revenue change

Profit Margin

-8.4%

How much profit the company keeps from each dollar of revenue

ROE

-9.4%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$9.00

-2% from current price — median analyst estimate

Recommendation

HOLD

Consensus view from 14 analysts covering this stock

About Avantor, Inc.

Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, peristaltic pumps, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Further, it provides scientific research support services, such as DNA extraction, bioreactor servicing, clinical and biorepository, compound management, cleanroom control, monitoring, maintenance, and sanitization services. The company was founded in 1904 and is headquartered in Radnor, Pennsylvania.

https://www.avantorsciences.com

Country: United States Employees: 13,500 Industry: Medical Instruments & Supplies

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

-0.768

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0890

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.517

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-37.9%

Historical annualised return based on price data

Max Drawdown

-73.3%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.94

Less volatile than the market — more defensive

52W High

$15.93

42% below the year high

52W Low

$7.27

26% above the year low

Avg Volume

9,566,377

Average daily shares traded — higher means easier to buy and sell

Short Ratio

3.8

Days it would take all short sellers to cover — higher means more crowded

Short % Float

6.9%

Moderate short interest

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.81

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

68.29

Heavy leverage — higher financial risk if revenues decline

Current Ratio

1.76

Healthy liquidity position

Quick Ratio

1.01

Like current ratio but excludes inventory — stricter test

Gross Margin

32.1%

Revenue left after cost of goods — higher means pricing power

Operating Margin

6.3%

Profit from core operations before interest and tax

Free Cash Flow

$489M

Positive — the business generates more cash than it spends

Revenue (TTM)

$6.6B

Total revenue over the last 12 months

Net Income

$-551,400,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$19.00

Target Median

$9.00

Target Low

$7.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go